FDA Makes It Easier to Sell Some Unclassified Gadgets
Published Date: 6/5/2026
Notice
Summary
The FDA is planning to exempt some unclassified medical devices from the usual premarket notification rules, making it easier and faster for these devices to reach the market. This change affects manufacturers of certain medical devices and could save them time and money. The new guidance is effective starting June 5, 2026, but the FDA is still open to feedback from the public.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Some devices exempted from 510(k)
The FDA announced on June 5, 2026 that it intends to exempt certain unclassified medical devices from premarket notification (510(k)) requirements. During this time, FDA does not intend to enforce 510(k) requirements for those devices and does not expect manufacturers to submit 510(k)s, which may save manufacturers time and money.
Five product codes added to exemption list
The updated guidance (published June 5, 2026) adds five product codes that FDA assessed as meeting standards for exemption from premarket notification: LDK (Device, sensing, optical contour); MVV (Device, acupressure); MQZ (Prosthesis, nail); MIG (Strip, test isoniazid); and LXQ (Cup, eye). The update supersedes the June 2019 guidance and reflects FDA's current assessment that these device types meet exemption standards.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11308 — Medical Devices; Orthopedic Devices; Classification of the Resorbable Calcium Salt Bone Void Filler Containing a Single Approved Aminoglycoside Antibacterial
The FDA is officially putting a special bone filler that slowly dissolves and fights bacteria into a safer, easier-to-manage category called Class II. This change helps make sure the product is safe and effective while speeding up patient access to this cool new tech. It’s been in effect since May 2022, so companies and patients can expect smoother approvals and fewer hoops to jump through.
2026-11306 — Medical Devices; Orthopedic Devices; Classification of the Shoulder Joint Humeral (Hemi-Shoulder) Ceramic Head/Metallic Stem Cemented or Uncemented Prosthesis
The FDA is officially putting the shoulder joint humeral ceramic head/metallic stem prosthesis into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps patients get safer, innovative shoulder implants faster and makes life easier for makers by lowering regulatory costs. The new classification is effective June 5, 2026, but has been in effect since December 16, 2022.
2026-11302 — Medical Devices; Orthopedic Devices; Classification of the Absorbable Metallic Bone Fixation Fastener
The FDA is officially classifying absorbable metallic bone fixation fasteners as Class II devices with special safety rules, making them easier to get to patients while keeping them safe and effective. This change helps doctors and patients by reducing red tape and encouraging new, helpful bone-fixing tech. The new rules took effect on June 5, 2026, but have been in place since March 29, 2023, so manufacturers should already be on board.
2026-11060 — Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities-Questions and Answers; Revised Draft Guidance for Industry; Availability
The FDA just released a revised draft guide to help drug and device makers share important cost and coverage info with insurance companies and similar groups. This update clears up how to talk about approved products, unapproved products, and new uses, making it easier for everyone to understand the rules. Companies should send their feedback by August 3, 2026, so the FDA can finalize the guide—potentially speeding up coverage decisions and saving money.
2026-11062 — Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
The FDA is officially pulling the plug on 16 generic drug approvals because the companies told them these medicines aren’t being sold anymore. This change kicks in on July 6, 2026, and it won’t stop companies from trying again later if they want. If you’re a drug maker or just curious, this means fewer old approvals cluttering the books and a cleaner, fresher drug list.
2026-11101 — Third Annual Animal Drug User Fee Educational Conference; Public Meeting
The FDA is hosting its Third Annual Animal Drug User Fee Educational Conference on July 7, 2026, to help drug makers and animal health experts understand the new animal drug approval process. This free event is both in-person and online, making it easy to join. Stakeholders should register early and can send feedback within 90 days after the meeting to help shape future policies and fees.
Previous / Next Documents
Previous: 2026-11296 — Notice of Determinations and Request for Comments Concerning Actions in Section 301 Investigations of Acts, Policies, and Practices of Various Economies Related to the Failure To Impose and Effectively Enforce a Prohibition on the Importation of Goods Produced With Forced Labor
The U.S. Trade Representative found that many countries aren’t stopping goods made with forced labor from entering the U.S. To fix this, they’re planning to add extra taxes (tariffs) on products from these countries, with rates between 10% and 12.5%. They’re also offering a special deal for some clothing imports and want your thoughts before finalizing these changes by early July 2026.
Next: 2026-11309 — 60-Day Notice of Proposed Information Collection: Service Coordinators in Multifamily Housing
HUD wants to collect updated info from service coordinators who help people in multifamily housing. They’re asking for public feedback over the next 60 days before finalizing the forms and rules. This helps make sure funds are used right and keeps support services running smoothly, with no new costs for those involved.